SK16322002A3 - Sulfónamidové deriváty - Google Patents

Sulfónamidové deriváty Download PDF

Info

Publication number
SK16322002A3
SK16322002A3 SK1632-2002A SK16322002A SK16322002A3 SK 16322002 A3 SK16322002 A3 SK 16322002A3 SK 16322002 A SK16322002 A SK 16322002A SK 16322002 A3 SK16322002 A3 SK 16322002A3
Authority
SK
Slovakia
Prior art keywords
compound
formula
pharmaceutically acceptable
patient
acceptable salt
Prior art date
Application number
SK1632-2002A
Other languages
English (en)
Slovak (sk)
Inventor
James Abraham Aikins
Andrew Hendley Fray
William David Miller
Paul Leslie Ornstein
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK16322002A3 publication Critical patent/SK16322002A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1632-2002A 2000-05-19 2001-05-04 Sulfónamidové deriváty SK16322002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20582200P 2000-05-19 2000-05-19
PCT/US2001/011746 WO2001090056A1 (fr) 2000-05-19 2001-05-04 Derives de sulfonamide

Publications (1)

Publication Number Publication Date
SK16322002A3 true SK16322002A3 (sk) 2003-05-02

Family

ID=22763775

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1632-2002A SK16322002A3 (sk) 2000-05-19 2001-05-04 Sulfónamidové deriváty

Country Status (25)

Country Link
US (2) US6720357B2 (fr)
EP (1) EP1296944A1 (fr)
JP (1) JP2003534315A (fr)
KR (1) KR20030007643A (fr)
CN (1) CN1429206A (fr)
AR (1) AR028590A1 (fr)
AU (1) AU2001262936A1 (fr)
BR (1) BR0110871A (fr)
CA (1) CA2409829A1 (fr)
CZ (1) CZ20023796A3 (fr)
DZ (1) DZ3344A1 (fr)
EA (1) EA004868B1 (fr)
EC (1) ECSP014079A (fr)
HR (1) HRP20020917A2 (fr)
HU (1) HUP0302291A3 (fr)
IL (1) IL152154A0 (fr)
MX (1) MXPA02010021A (fr)
NO (1) NO20025533L (fr)
NZ (1) NZ521620A (fr)
PE (1) PE20011260A1 (fr)
PL (1) PL358184A1 (fr)
SK (1) SK16322002A3 (fr)
SV (1) SV2002000458A (fr)
WO (1) WO2001090056A1 (fr)
ZA (1) ZA200208746B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (fr) * 2003-07-17 2005-02-17 Eli Lilly And Company Polytherapie pour le traitement de troubles cognitifs ou de psychoses
US20070105914A1 (en) * 2003-09-18 2007-05-10 Armstrong Helen M Substituted sulfonamides
PT2445883E (pt) 2009-06-26 2014-10-27 Pfizer Sulfonamidas heterocíclicas, suas utilizações e composições farmacêuticas
KR101569842B1 (ko) 2009-09-30 2015-11-17 삼성전자 주식회사 텔레비전용 전원공급유닛 및 이를 포함하는 텔레비전
WO2011109398A2 (fr) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
EP3311842A1 (fr) 2013-06-13 2018-04-25 VeroScience LLC Compositions et procédés de traitement des troubles métaboliques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
PE20000943A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida
US6358982B1 (en) 1998-07-31 2002-03-19 Eli Lilly And Company Heterocyclyl sulphonamide derivatives
AU5235599A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
PL358184A1 (en) 2004-08-09
BR0110871A (pt) 2003-02-11
EA200201232A1 (ru) 2003-04-24
EA004868B1 (ru) 2004-08-26
NZ521620A (en) 2004-08-27
ZA200208746B (en) 2004-02-10
KR20030007643A (ko) 2003-01-23
AR028590A1 (es) 2003-05-14
US20030233015A1 (en) 2003-12-18
US6803484B2 (en) 2004-10-12
NO20025533L (no) 2003-01-20
DZ3344A1 (fr) 2001-11-29
CZ20023796A3 (cs) 2003-04-16
CN1429206A (zh) 2003-07-09
NO20025533D0 (no) 2002-11-18
US6720357B2 (en) 2004-04-13
CA2409829A1 (fr) 2001-11-29
IL152154A0 (en) 2003-05-29
ECSP014079A (es) 2002-02-25
MXPA02010021A (es) 2003-02-12
AU2001262936A1 (en) 2001-12-03
SV2002000458A (es) 2002-10-24
WO2001090056A1 (fr) 2001-11-29
PE20011260A1 (es) 2001-12-11
HRP20020917A2 (en) 2004-02-29
HUP0302291A2 (hu) 2003-11-28
JP2003534315A (ja) 2003-11-18
EP1296944A1 (fr) 2003-04-02
HUP0302291A3 (en) 2006-11-28
US20040143020A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
SK16322002A3 (sk) Sulfónamidové deriváty
EP1246797B1 (fr) Derives de sulfonamide de cyclopentyle
EP1100497B1 (fr) Derives de sulfamide heterocyclyles
SK16312002A3 (sk) Sulfónamidové deriváty
AU2007333247B2 (en) AMPA receptor potentiators
CA2339091A1 (fr) Sulfamides
US6639107B1 (en) Cyclopentyl sulfonamide derivatives
US20040235957A1 (en) Use of sulfonamide derivatives as pharmaceuticals compounds
US20040198833A1 (en) Acetylenic sulfonamide derivatives

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure